Back to Search Start Over

Potential Benefit of Add-on Δ9-Tetrahydrocannabinol in Pediatric Drug-Resistant Epilepsy: A Case Series.

Authors :
Nowicki M
Bourgeois-Tardif S
Diaz PL
Hebert FO
Sanon NT
Champagne PO
Major P
Sell E
Bitton J
Lewis E
Weil AG
Source :
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [Can J Neurol Sci] 2022 Jul; Vol. 49 (4), pp. 595-597. Date of Electronic Publication: 2021 Jun 29.
Publication Year :
2022

Abstract

We present five cases of pediatric drug-resistant epilepsy (DRE) that failed management using high cannabidiol (CBD) doses, but had significant reduction in seizure frequency with reintroduction or increasing doses of tetrahydrocannabinol (THC). There is growing evidence supporting the use of whole-plant CBD-rich extracts (containing THC and other cannabinoids) in the treatment of pediatric DRE. Based on our experiences and reports in the literature, we propose that, in patients who fail management with an initial trial of high-dose CBD-focused therapy, there may be a role for add-on THC-focused formulations.

Details

Language :
English
ISSN :
0317-1671
Volume :
49
Issue :
4
Database :
MEDLINE
Journal :
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Publication Type :
Academic Journal
Accession number :
34183079
Full Text :
https://doi.org/10.1017/cjn.2021.151